Targeted Therapies Offer Fresh Options in Urothelial Carcinoma

Jason Harris
Published: Friday, May 17, 2019
Daniel P. Petrylak, MD

Daniel P. Petrylak, MD
Oncologists looking for options beyond immuno-oncology (I/O) for treating patients with metastatic urothelial carcinoma (mUC) may soon have a range of targeted therapy choices, according to Daniel P. Petrylak, MD.

Petrylak, a professor of medicine and urology at Yale School of Medicine in New Haven, Connecticut, discussed the growing potential for targeted therapies in mUC at the New York GU™: 12th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies meeting.

In April, the FDA granted an accelerated approval to erdafitinib (Balversa), an oral pan-fibroblast growth factor receptor (FGFR) inhibitor that is the first targeted therapy approved for mUC.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication